---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-008603"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-01-24T23:59:59+00:00"
generated_at: "2026-05-27T12:23:37.889835+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics reports updated Phase 1/2a data for [212Pb]VMT-α-NET: 3 objective responses, no DLTs

## Summary
- Three objective responses (1 confirmed, 2 unconfirmed) in Cohort 2 at 5.0 mCi dose; 5 stable disease; 1 progressive disease.
- No dose-limiting toxicities, grade 4/5 events, or SAEs reported; hematologic AEs were grade 1-2 only.
- Additional 11 patients dosed in Cohort 2 since August 2024, totaling 18 as of Dec 31, 2024.
- Company pursuing dose escalation to Cohort 3 after FDA consultation; data submitted to FDA in December 2024.

## SEC filing metadata
- accession: 0000950170-25-008603
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-01-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000095017025008603/0000950170-25-008603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000095017025008603/catx-20250124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-008603
- JSON: https://secwatch.observer/filing/0000950170-25-008603.json
- Plain text: https://secwatch.observer/filing/0000950170-25-008603.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.